Aim: The knowledge of the molecular signals that control cell differentiation into cardiomyocytes is critical to apply cell-based therapies and repair an injured heart. The transcription factor Pitx2 has essential roles in the development of different organs including the heart. Although a direct role of Pitx2 in the developing myocardium has recently been reported, the molecular pathways driven by Pitx2 as well as its cardiac target genes remain largely unexplored. The aim of this study was to unravel the molecular mechanisms driven by Pitx2 during the process of cardiomyocyte differentiation in vitro in mouse embryonic stem cell-derived cardiomyocytes. Methods and Results: Pitx2c was overexpressed in the R1-embryonic stem cell line. mRNA levels and protein distribution of several specific cardiac genes were analyzed by real-time PCR and immunohistochemistry experiments in R1-embryonic stem cell-derived beating areas at different stages of in vitro differentiation. Our results show that overexpression of Pitx2c in embryonic stem cell-derived cardiomyocytes is able to dynamically upregulate several cardiac-enriched transcription factors such as Isl1, Mef2c and Gata4. Additionally, Pitx2c induces the expression of chamber-specific cardiac genes such as Tbx5, Nppa and Cx40. These data were validated in an in vivo model of Pitx2 loss of function. Conclusion: Taken together, these results demonstrate that Pitx2 plays a major role reinforcing the transcriptional program of cardiac differentiation.

Keywords:
Embryonic stem cells, Cardiomyocytes, Differentiation, Cell culture, Pitx2c
1.
Ai, D., W. Liu, L. Ma, F. Dong, M.F. Lu, D. Wang, M.P. Verzi, C. Cai, P.J. Gage, S. Evans, B.L. Black, N.A. Brown, J.F. Martin (2006) Pitx2 regulates cardiac left-right asymmetry by patterning second cardiac lineage-derived myocardium. Dev Biol 296: 437–449.
2.
Black, B.L. (2007) Transcriptional pathways in second heart field development. Semin Cell Dev Biol 18: 67–76.
3.
Brand, T. (2003) Heart development: molecular insights into cardiac specification and early morphogenesis. Dev Biol 258: 1–19.
4.
Campione, M., M.A. Ros, J.M. Icardo, E. Piedra, V.M. Christoffels, A. Schweickert, M. Blum, D. Franco, A.F. Moorman (2001) Pitx2 expression defines a left cardiac lineage of cells: evidence for atrial and ventricular molecular isomerism in the iv/iv mice. Dev Biol 231: 252–264.
5.
de Lange, F.J., A.F. Moorman, V.M. Christoffels (2003) Atrial cardiomyocyte-specific expression of Cre recombinase driven by an Nppa gene fragment. Genesis 37: 1–4.
6.
Delorme, B., E. Dahl, T. Jarry-Guichard, J.P. Briand, K. Willecke, D. Gros, M. Theveniau-Ruissy (1997) Expression pattern of connexin gene products at the early developmental stages of the mouse cardiovascular system. Circ Res 81: 423–437.
7.
Dodou, E., M.P. Verzi, J.P. Anderson, S.M. Xu, B.L. Black (2004) Mef2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development. Development 131: 3931–3942.
8.
Doss, M.X., J. Winkler, S. Chen, R. Hippler-Altenburg, I. Sotiriadou, M. Halbach, K. Pfannkuche, H. Liang, H. Schulz, O. Hummel, N. Hübner, R. Rottscheidt, J. Hescheler, A. Sachinidis (2007) Global transcriptome analysis of murine embryonic stem cell-derived cardiomyocytes. Genome Biol 8: R56.
9.
Gage, P.J., H. Suh, S.A. Camper (1999) Dosage requirement of Pitx2 for development of multiple organs. Development 126: 4643–4651.
10.
Galli, D., J.N. Dominguez, S. Zaffran, A. Munk, N.A. Brown, M.E. Buckingham (2008) Atrial myocardium derives from the posterior region of the second heart field, which acquires left-right identity as Pitx2c is expressed. Development 135: 1157–1167.
11.
Ganga, M., H.M. Espinoza, C.J. Cox, L. Morton, T.A. Hjalt, Y. Lee, B.A. Amendt (2003) PITX2 isoform-specific regulation of atrial natriuretic factor expression: synergism and repression with Nkx2.5. J Biol Chem 278: 22437–22445.
12.
Gherzi, R., M. Trabucchi, M. Ponassi, I.E. Gallouzi, M.G. Rosenfeld, P. Briata (2010) Akt2-mediated phosphorylation of Pitx2 controls Ccnd1 mRNA decay during muscle cell differentiation. Cell Death Differ 17: 975–983.
13.
Habets, P.E., A.F. Moorman, D.E. Clout, M.A. van Roon, M. Lingbeek, M. van Lohuizen, M. Campione, V.M. Christoffels (2002) Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: implications for cardiac chamber formation. Genes Dev 16: 1234–1246.
14.
Hidaka, K., J.K. Lee, H.S. Kim, C.H. Ihm, A. Iio, M. Ogawa, S. Nishikawa, I. Kodama, T. Morisaki (2003) Chamber-specific differentiation of Nkx2.5-positive cardiac precursor cells from murine embryonic stem cells. FASEB J 17: 740–742.
15.
Houweling, A.C., M.M. van Borren, A.F. Moorman, V.M. Christoffels (2005) Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease. Cardiovasc Res 67: 583–593.
16.
Kelly, R.G., M.E. Buckingham (2002) The anterior heart-forming field: voyage to the arterial pole of the heart. Trends Genet 18: 210–216.
17.
Klug, M.G., M.H. Soonpaa, G.Y. Koh, L.J. Field (1996) Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest 98: 216–224.
18.
Liu, C., W. Liu, M.F. Lu, N.A. Brown, J.F. Martin (2001) Regulation of left-right asymmetry by thresholds of Pitx2c activity. Development 128: 2039–2048.
19.
Lyons, G.E., S. Schiaffino, D. Sassoon, P. Barton, M. Buckingham (1990) Developmental regulation of myosin gene expression in mouse cardiac muscle. J Cell Biol 111: 2427–2436.
20.
Ma, Q., B. Zhou, W.T. Pu (2008) Reassessment of Isl1 and Nkx2–5 cardiac fate maps using a Gata4-based reporter of Cre activity. Dev Biol 323: 98–104.
21.
Maltsev, V.A., A.M. Wobus, J. Rohwedel, M. Bader, J. Hescheler (1994) Cardiomyocytes differentiated in vitro from embryonic stem cells developmentally express cardiac-specific genes and ionic currents. Circ Res 75: 233–244.
22.
Martinez-Fernandez, S., F. Hernandez-Torres, D. Franco, G.E. Lyons, F. Navarro, A.E. Aranega (2006) Pitx2c overexpression promotes cell proliferation and arrests differentiation in myoblasts. Dev Dyn 235: 2930–2939.
23.
Nakashima, Y., K. Ono, Y. Yoshida, Y. Kojima, T. Kita, M. Tanaka, T. Kimura (2009) The search for Nkx2–5-regulated genes using purified embryonic stem cell-derived cardiomyocytes with Nkx2–5 gene targeting. Biochem Biophys Res Commun 390: 821–826.
24.
Nowotschin, S., J. Liao, P.J. Gage, J.A. Epstein, M. Campione, B.E. Morrow (2006) Tbx1 affects asymmetric cardiac morphogenesis by regulating Pitx2 in the secondary heart field. Development 133: 1565–1573.
25.
Schweickert, A., M. Campione, H. Steinbeisser, M. Blum (2000) Pitx2 isoforms: involvement of Pitx2c but not Pitx2a or Pitx2b in vertebrate left-right asymmetry. Mech Dev 90: 41–51.
26.
Tessari, A., M. Pietrobon, A. Notte, G. Cifelli, P.J. Gage, M.D. Schneider, G. Lembo, M. Campione (2008) Myocardial Pitx2 differentially regulates the left atrial identity and ventricular asymmetric remodeling programs. Circ Res 102: 813–822.
27.
Yamanaka, S., I. Zahanich, R.P. Wersto, K.R. Boheler (2008) Enhanced proliferation of monolayer cultures of embryonic stem (ES) cell-derived cardiomyocytes following acute loss of retinoblastoma. PLoS ONE 3: 1–15.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.